No reason not to expand them, except for:

1. Having sufficient funding to reach some sort of liquidity event for the studies/drugs already underway; and

2. Avoiding the issue in many people's minds of eventual resistence developing, to either B or K.

Remember, so many drugs have run into resistance in the past that a lot of people fixate on avoiding that, notwithstanding the less likely issue with our drugs.